Brief: Shanghai Public Health Clinical Center Completed Patient Enrollment In Clinical Study Of Pd-L1 Antibody Asc22 (Envafolimab) In Combination With Chidamide For Functional Cure Of HIV Infection
15/09/2022 11:12
Sept 15 (Reuters) - Ascletis Pharma Inc 1672.HK :
* SHANGHAI PUBLIC HEALTH CLINICAL CENTER COMPLETED PATIENT
ENROLLMENT IN CLINICAL STUDY OF PD-L1 ANTIBODY ASC22
(ENVAFOLIMAB) IN COMBINATION WITH CHIDAMIDE FOR FUNCTIONAL CURE
OF HIV INFECTION
Source text for Eikon: ID:nPn4Lwzlta
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026